In a phase 1b study, the safety and pharmacokinetics (PK) of combining regorafenib with cetuximab (an EGFR inhibitor) were assessed in patients with advanced refractory solid tumors, including gastrointestinal stromal tumors, colorectal cancer, and HCC [424]. This evidence concerns the gene EGFR and hepatocellular carcinoma.